Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2022

May 17, 2022

SELL
$2.42 - $3.98 $245,872 - $404,368
-101,600 Reduced 44.41%
127,200 $379,000
Q4 2021

Feb 15, 2022

BUY
$3.11 - $4.61 $550,470 - $815,970
177,000 Added 341.7%
228,800 $890,000
Q3 2021

Nov 16, 2021

SELL
$2.65 - $4.62 $21,995 - $38,346
-8,300 Reduced 13.81%
51,800 $222,000
Q1 2021

May 18, 2021

SELL
$3.14 - $4.84 $290,764 - $448,184
-92,600 Reduced 60.64%
60,100 $200,000
Q4 2020

Feb 17, 2021

BUY
$2.76 - $4.97 $421,451 - $758,919
152,700 New
152,700 $542,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $523M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.